Jonathan D. Glass on In Small Trial, EH301 Appears to Halt Progression of ALS
COMMENT The data shown here seems extraordinary in that the active group seemed to actually “improve” over the four-month trial period. If true, fantastic! But it reminds me a bit of the Italian trial of lithium—amazing results in a small cohort and completely ...